Shattuck Labs, Inc.(STTK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

STTK Shattuck Labs, Inc.

Post-Mkt 03-09 19:35:51 EDT

6.02

+0.03

+0.50%

盘后5.89

-0.13-2.14%

18:07 EDT

High6.25	Low5.75	Vol836.84K
Open6.04	D1 Closing5.99	Amplitude8.35%
Mkt Cap430.82M	Tradable Cap278.25M	Total Shares71.56M
T/O5.02M	T/O Rate1.81%	Tradable Shares46.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"STTK","market":"US","secType":"STK","nameCN":"Shattuck Labs, Inc.","latestPrice":6.02,"timestamp":1773086400000,"preClose":5.99,"halted":0,"volume":836839,"hourTrading":{"tag":"盘后","latestPrice":5.8911,"preClose":6.02,"latestTime":"18:07 EDT","volume":3282,"amount":19717.6530966,"timestamp":1773094077493,"change":-0.1289,"changeRate":-0.021412,"amplitude":0.024917},"delay":0,"changeRate":0.005008347245408908,"floatShares":46220700,"shares":71564217,"eps":-0.70143,"marketStatus":"Post-Mkt","change":0.03,"latestTime":"03-09 19:35:51 EDT","open":6.04,"high":6.25,"low":5.75,"amount":5024974.674851,"amplitude":0.083472,"askPrice":6.31,"askSize":4,"bidPrice":5.89,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-0.70143,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773100800000},"marketStatusCode":4,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":5.99,"preHourTrading":{"tag":"盘前","latestPrice":6.05,"preClose":5.99,"latestTime":"09:29 EDT","volume":8916,"amount":55360.4907384,"timestamp":1773062999999,"change":0.06,"changeRate":0.010017,"amplitude":0.043406},"postHourTrading":{"tag":"盘后","latestPrice":5.8911,"preClose":6.02,"latestTime":"18:07 EDT","volume":3282,"amount":19717.6530966,"timestamp":1773094077493,"change":-0.1289,"changeRate":-0.021412,"amplitude":0.024917},"volumeRatio":0.595692,"impliedVol":3.9569,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/STTK/tweets","defaultTab":"tweets","newsList":[{"id":"2617633655","title":"Shattuck Labs Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2617633655","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617633655?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:53","pubTimestamp":1772805180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/STTK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 08:53 ET (13:53 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STTK"],"gpt_icon":0},{"id":"2617684682","title":"Wedbush Raises Price Target on Shattuck Labs to $8 From $4, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2617684682","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617684682?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:39","pubTimestamp":1772797181,"startTime":"0","endTime":"0","summary":"Shattuck Labs (STTK) has an average rating of buy and mean price target of $9.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["STTK"],"gpt_icon":0},{"id":"2617549318","title":"Shattuck Labs Publishes Corporate Presentation on DR3-Blocking Antibodies for Inflammatory and Immune-Mediated Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2617549318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617549318?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:37","pubTimestamp":1772710652,"startTime":"0","endTime":"0","summary":"Shattuck Labs Inc. outlined its focus on developing monoclonal and bispecific antibodies that block DR3  for inflammatory and immune-mediated diseases. The company highlighted its lead candidate, SL-325, a potentially first-in-class DR3 blocking antibody designed to inhibit the TL1A/DR3 pathway, with Phase 2 development planned in Crohn’s disease and Phase 1 enrollment in healthy volunteers nearly complete. Shattuck also described a preclinical pipeline that includes SL-425, a half-life extended DR3 blocking antibody, and DR3-based bispecific programs for autoimmune indications, and reported cash and cash equivalents of $78.1 million as of Dec. 31, 2025 and a preliminary $94.5 million as of Feb. 28, 2026, with runway expected into 2029. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLbQMZnc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STTK","BK4139"],"gpt_icon":0},{"id":"2617461965","title":"Shattuck Labs expects available cash to fund operations into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2617461965","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617461965?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:21","pubTimestamp":1772709690,"startTime":"0","endTime":"0","summary":"The company said, “As of December 31, 2025, cash and cash equivalents and short-term investments were approximately $78.1M. Shattuck’s current cash...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/shattuck-labs-expects-available-cash-to-fund-operations-into-2029-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/shattuck-labs-expects-available-cash-to-fund-operations-into-2029-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["STTK","BK4139"],"gpt_icon":0},{"id":"2617546522","title":"Shattuck Labs Q4 EPS $(0.12) Beats $(0.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617546522","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617546522?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:16","pubTimestamp":1772709416,"startTime":"0","endTime":"0","summary":"Shattuck Labs (NASDAQ:STTK) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 17.81 percent. This is a 67.57 percent increase over losses of $(0.37) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51060861/shattuck-labs-q4-eps-0-12-beats-0-15-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STTK"],"gpt_icon":0},{"id":"2617254654","title":"BRIEF-Shattuck Labs Q4 Net Income USD -12.593 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617254654","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617254654?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:15","pubTimestamp":1772709345,"startTime":"0","endTime":"0","summary":"BRIEF-Shattuck Labs Q4 Net Income USD -12.593 Million\n\n\nMar 05 (Reuters) - Shattuck Labs Q4 income from operations USD -13.373 million.\n\nQ4 basic EPS USD -0.12","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLXB263E6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","STTK"],"gpt_icon":0},{"id":"2617546547","title":"Shattuck Labs Q4 net loss hits USD 12.6 million (-32.6%)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617546547","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617546547?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:15","pubTimestamp":1772709318,"startTime":"0","endTime":"0","summary":"Shattuck Labs Q4 net loss hits USD 12.6 million (-32.6%)               Shattuck reported Q4 2025 net loss of USD 12.6 million and a net loss per share of USD 0.12, with R&D expenses of USD 9.1 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL6Sc15Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU0314104364.USD","BK4585","IE00B3QW5Z07.USD","BK4588","STTK","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","SG9999014013.SGD","IE00B64PRP62.GBP","BK4139","SG9999014039.USD","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD"],"gpt_icon":0},{"id":"2617549897","title":"Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2617549897","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617549897?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:15","pubTimestamp":1772709300,"startTime":"0","endTime":"0","summary":"Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/05/3249960/0/en/Shattuck-Labs-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","STTK","BK4139","PK","BK4181"],"gpt_icon":0},{"id":"2614803360","title":"Shattuck Labs Announces Participation in Upcoming March Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2614803360","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614803360?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:00","pubTimestamp":1772024400,"startTime":"0","endTime":"0","summary":"AUSTIN, TX and DURHAM, NC, Feb.  25, 2026  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244544/0/en/Shattuck-Labs-Announces-Participation-in-Upcoming-March-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","STTK"],"gpt_icon":0},{"id":"2609272596","title":"Shattuck Labs to Join Piper Sandler Virtual Novel Targets in Immunology Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2609272596","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609272596?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:30","pubTimestamp":1770384620,"startTime":"0","endTime":"0","summary":"Shattuck Labs Inc., a clinical-stage biotechnology company specializing in novel therapeutics for inflammatory and immune-mediated diseases, will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026, at 2:00 PM ET. The company's CEO Taylor Schreiber, M.D., Ph.D., CFO Andrew R. Neill, and Vice President of Clinical Development Michael Choi, M.D., will represent Shattuck Labs during the event. A replay of the prerecorded presentation will be available on the Events and Presentations section of Shattuck Labs' website starting at 2:00 PM ET on February 12, 2026, and will be archived for up to 30 days following the presentation date. A webcast link is provided: HERE.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL92DwjH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014021.USD","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","BK4112","BK4585","LU0053671581.USD","LU2210150020.SGD","SG9999014013.SGD","BK4127","IE00BKPKM429.USD","SG9999014039.USD","LU2095319765.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU0314104364.USD","STTK","PIPR","SG9999014005.SGD"],"gpt_icon":0},{"id":"2609591121","title":"Shattuck Labs Insider Buyers Net US$637k Despite 12% Stock Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2609591121","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609591121?lang=en_us&edition=fundamental","pubTime":"2026-02-06 18:44","pubTimestamp":1770374698,"startTime":"0","endTime":"0","summary":"Insiders who purchased Shattuck Labs, Inc. ( NASDAQ:STTK ) shares in the past 12 months are unlikely to be deeply...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sttk/shattuck-labs/news/shattuck-labs-insider-buyers-net-us637k-despite-12-stock-dec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sttk/shattuck-labs/news/shattuck-labs-insider-buyers-net-us637k-despite-12-stock-dec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","STTK"],"gpt_icon":0},{"id":"2606712592","title":"Shattuck Labs Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2606712592","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606712592?lang=en_us&edition=fundamental","pubTime":"2026-01-28 22:03","pubTimestamp":1769608980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/STTK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 09:03 ET (14:03 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STTK"],"gpt_icon":0},{"id":"2606792299","title":"Shattuck Labs initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2606792299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606792299?lang=en_us&edition=fundamental","pubTime":"2026-01-28 17:55","pubTimestamp":1769594116,"startTime":"0","endTime":"0","summary":"Piper Sandler initiated coverage of Shattuck Labs (STTK) with an Overweight rating and $15 price target The company’s SL-325 offers a “differentiat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/shattuck-labs-initiated-with-an-overweight-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/shattuck-labs-initiated-with-an-overweight-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["STTK"],"gpt_icon":0},{"id":"2605436434","title":"BRIEF-Shattuck Labs Inc Enters $75 Million Common Stock Sales Agreement With Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2605436434","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605436434?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:40","pubTimestamp":1769121618,"startTime":"0","endTime":"0","summary":"BRIEF-Shattuck Labs Inc Enters $75 Million Common Stock Sales Agreement With Leerink Partners Jan 22  - Shattuck Labs Inc STTK.O:SHATTUCK LABS INC - ENTERS $75 MILLION COMMON STOCK SALES AGREEMENT WITH LEERINK PARTNERS - SEC FILINGSource text: [ID:n0001193125-26-019670]Further company coverage: STTK.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nFWN3YN1D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","STTK"],"gpt_icon":0},{"id":"2605448732","title":"Shattuck Labs Inc - Enters $75 Mln Common Stock Sales Agreement With Leerink Partners - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2605448732","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605448732?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:21","pubTimestamp":1769120485,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nFWN3YN1D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["STTK","BK4139"],"gpt_icon":0},{"id":"2603655382","title":"Shattuck Labs Files $200 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2603655382","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603655382?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:23","pubTimestamp":1768343000,"startTime":"0","endTime":"0","summary":"Shattuck Labs  filed a shelf registration statement with US regulators on late Tuesday for the potential sale of up to $200 million in securities, to be offered from time to time.The filing covers common stock, preferred stock, debt securities, warrants and units.The company said the offering proceeds will fund clinical trials, product development, general corporate needs, and potential acquisitions, with unused funds held in safe investments.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["STTK","BK4139"],"gpt_icon":0},{"id":"2603658586","title":"Shattuck Labs Inc - May Issue up to $200 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603658586","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603658586?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:17","pubTimestamp":1768339057,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE16R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","STTK"],"gpt_icon":0},{"id":"2601339817","title":"Shattuck Labs Is Maintained at Neutral by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2601339817","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601339817?lang=en_us&edition=fundamental","pubTime":"2026-01-07 02:50","pubTimestamp":1767725400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/STTK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 13:50 ET (18:50 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STTK"],"gpt_icon":0},{"id":"2595131557","title":"Shattuck Labs, Inc.'s (NASDAQ:STTK) biggest owners are retail investors who got richer after stock soared 10% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2595131557","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595131557?lang=en_us&edition=fundamental","pubTime":"2025-12-30 18:22","pubTimestamp":1767090164,"startTime":"0","endTime":"0","summary":"Key Insights Shattuck Labs' significant retail investors ownership suggests that the key decisions are influenced by...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sttk/shattuck-labs/news/shattuck-labs-incs-nasdaqsttk-biggest-owners-are-retail-inve","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sttk/shattuck-labs/news/shattuck-labs-incs-nasdaqsttk-biggest-owners-are-retail-inve","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","BK4139","SQQQ","USAW.SI","STTK","NVIW.SI","TQQQ",".IXIC","PSQ","QID","NQmain","USJW.SI","TSYW.SI","MNQmain"],"gpt_icon":1},{"id":"2591062434","title":"Shattuck Labs Grants Inducement Stock Options to New Hire","url":"https://stock-news.laohu8.com/highlight/detail?id=2591062434","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591062434?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:15","pubTimestamp":1765833307,"startTime":"0","endTime":"0","summary":"Shattuck Labs Inc. has granted inducement equity awards to a newly-hired non-executive officer. The awards consist of non-qualified stock options to purchase 206,000 shares of common stock at an exercise price of $3.23 per share. The options have a maximum term of 10 years, with 25% vesting on November 17, 2026, and the remaining shares vesting in equal monthly installments over the following 36 months. These stock options were granted outside of the company's 2020 Equity Incentive Plan but generally follow the same terms and conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire  on December 15, 2025, and is solely responsible for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLbwC0ll:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","BK4588","SG9999014013.SGD","SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","STTK","IE00B3QW5Z07.USD","BK4139","LU2210149790.SGD","LU0314104364.USD","BK4112","SG9999014021.USD","IE00BGHQF748.EUR","LU2210150020.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shattucklabs.com","stockEarnings":[{"period":"1week","weight":0.5281},{"period":"1month","weight":0.5558},{"period":"3month","weight":0.9323},{"period":"6month","weight":2.8645},{"period":"1year","weight":3.5038},{"period":"ytd","weight":0.6411}],"compareEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0201},{"period":"3month","weight":-0.0194},{"period":"6month","weight":0.0388},{"period":"1year","weight":0.174},{"period":"ytd","weight":-0.014}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.152423},{"month":2,"riseRate":0.5,"avgChangeRate":-0.039398},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.090873},{"month":4,"riseRate":0.8,"avgChangeRate":0.084733},{"month":5,"riseRate":0.2,"avgChangeRate":-0.177233},{"month":6,"riseRate":0.6,"avgChangeRate":-0.015781},{"month":7,"riseRate":0.2,"avgChangeRate":-0.098212},{"month":8,"riseRate":0.2,"avgChangeRate":-0.030277},{"month":9,"riseRate":0.2,"avgChangeRate":0.181582},{"month":10,"riseRate":0.2,"avgChangeRate":-0.168269},{"month":11,"riseRate":0.5,"avgChangeRate":-0.021423},{"month":12,"riseRate":1,"avgChangeRate":0.656999}],"exchange":"NASDAQ","name":"Shattuck Labs, Inc.","nameEN":"Shattuck Labs, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shattuck Labs, Inc.(STTK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shattuck Labs, Inc.(STTK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shattuck Labs, Inc.,STTK,Shattuck Labs, Inc.股票,Shattuck Labs, Inc.股票老虎,Shattuck Labs, Inc.股票老虎国际,Shattuck Labs, Inc.行情,Shattuck Labs, Inc.股票行情,Shattuck Labs, Inc.股价,Shattuck Labs, Inc.股市,Shattuck Labs, Inc.股票价格,Shattuck Labs, Inc.股票交易,Shattuck Labs, Inc.股票购买,Shattuck Labs, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shattuck Labs, Inc.(STTK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shattuck Labs, Inc.(STTK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}